Distributional cost-effectiveness analysis in genomic medicine: Considerations for addressing health equity.
Smith HS. et al, (2025), Value Health
Diagnosing Burkitt Lymphoma in Sub-Saharan Africa by Sequencing of Circulating Tumour DNA: a Comparative Microcosting Study
MORRELL L. et al, (2025), Value in Health Regional Issues
Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity: the By-Band-Sleeve multi-centre, open label, three-group randomised controlled trial
POUWELS K. et al, (2025), The Lancet Diabetes and Endocrinology
Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework.
Smith HS. et al, (2025), Appl Health Econ Health Policy
How, why and when are delayed (back-up) antibiotic prescriptions used in primary care? A realist review integrating concepts of uncertainty in healthcare
Mcleod M. et al, (2024), BMC Public Health, 24
Using orthopaedic health care resources efficiently: A cost analysis of day surgery for unicompartmental knee replacement.
Hlatshwako TG. et al, (2024), Knee, 49, 147 - 157
Health Care Costs After Genome-Wide Sequencing for Children With Rare Diseases in England and Canada.
Weymann D. et al, (2024), JAMA Netw Open, 7
Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use
ROOPE L. et al, (2024), Communications Medicine
Population screening requires robust evidence-genomics is no exception.
Turnbull C. et al, (2023), Lancet
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.
Kovács G. et al, (2023), Per Med
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.
Nagy B. et al, (2023), Per Med
Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
Koleva-Kolarova R. et al, (2023), Per Med
Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries
Szilberhorn L. et al, (2023), Personalized Medicine
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation
Koleva-Kolarova R. et al, (2023), Personalized Medicine
Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems
Koleva-Kolarova R. et al, (2023), Personalized Medicine